Safe practice of spine SBRT requires high-quality data about SC dose tolerance - Cohort study 2051 pts - 30 cases of RM, 19 of which G3 to G4 - 2a rate of G1-4 RM 1.8% - cord dose D0.1cc of 19.1Gy / Dmax of 20.8Gy = 1.0% risk of G3 to G4 RM at 2 years jamanetwork.com/journals/jamao…

Our work identifying a new spinal cord constraint for spine SBRT was published yesterday in JAMA Oncology Dan Higginson. Here, a thread: jamanetwork.com/journals/jamao…

Proud of my friend and co-resident Chris Jackson, MD, MS for answering this key question and building a >2,000 patient spine SBRT database from scratch. Next year, he’s joining MSK Rad Onc as faculty & will be treating spine so expect many more manuscripts from him in this area!

#mRNAvaccines for #PancreaticCancer (PDAC) PART4 1. Out today in nature nature.com/articles/s4158… 🧵👇🏽 [1/23]

Featured today by MSK Library: Advances in Vaccine-Based Therapies for Pancreatic Cancer #PancreaticCancer #CancerResearch #Immunotherapy #VaccineTherapy #Oncology #CancerTreatment #MedicalAdvances #PrecisionMedicine #HopeForACure #CancerInnovation Matthew McMillan, MD

Congratulations Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology Christopher Crane! Thanks The National Pancreas Foundation!

Proud of my mentor, Dr Chris Crane, who was awarded the Nobility in Science Award by the National Pancreas Foundation earlier tonight. Dr Crane’s work pioneering ablative radiotherapy for pancreatic cancer has been a game changer for the treatment of locally advanced PDAC!

Grateful for the opportunity to learn from Shankar Siva, a true master of his craft, who has trailblazed SABR for RCC and lung cancer.  Looking forward to future research collaborations! Huge thanks to Nancy Lee for organizing his visit!

The cancer community is better for having Puneeth Iyengar from Memorial Sloan Kettering Cancer Center in it. He has led much of key work in #RadOnc in lung & other cancers, & he is generous w/his time in educating others, including pts & caregivers, in programs like GRACE targeted Rx forum. 🙏

Congrats to the MSK Rad Onc Class of 2030! Looking forward to working with all of you!

Our secondary analysis of ARST1431 looking at local control with radiotherapy for pediatric rhabdomyosarcoma was published this week in IJROBP - The Red Journal. Thanks to Dr. Suzanne Wolden and the rest of COG Soft Tissue Sarcoma Group for your mentorship. redjournal.org/article/S0360-…

This finding in the manuscript by Piffko et al (pubmed.ncbi.nlm.nih.gov/40369065/) also reinforces the importance of treating all sites of metastasis and the primary (when safe/feasible). I know David Palma, MD, PhD and Shankar Siva already know this, but it’s a critical point to amplify

Key nuance from this paper: Radiotherapy significantly REDUCED the seeding of **NEW** metastases, but it triggers a local wound-healing response that can promote growth of **EXISTING** metastases. The authors elegantly showed that this resistance mechanism to RT is targetable

Congratulations to Daniel Wahl and his group whose paper on targeting glucose metabolism in GBM cells is now published in nature. the potential of amino acid diet restriction to slow tumor growth due. Groundbreaking work with big implications! UMich Rad Onc U-M Rogel Cancer Center

New discovery from our team defining how human brain cancers rewire the metabolism of the normal brain published today nature and led by Drew Scott nature.com/articles/s4158…

High rates of pCR (60%) and MPR (90%) with 2-4 cycles of neoadj Tislelizumab-chemo for unresectable LA-NSCLC, impressive even if the denominator includes patients who later received CRT. Ph3 RCTs of neoadj nivo-chemo for *resectable* NSCLC had pCR and MPR rates of 24-25% & 35-36%